tofacitinib · Xeljanz
Small molecule
Also known as CP-690550
Evidence outlook
Approved: Psoriatic Arthritis, Ulcerative Colitis, Rheumatoid Arthritis
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (6)
- Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers
- Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers
- Moderately to severely active ulcerative colitis in adult patients
- Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5). Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients...
- Rheumatoid Arthritis XELJANZ/XELJANZ XR (tofacitinib), in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of rheumatoid arthritis (RA) in adult patients with moderately to severely active RA who have had an inadequate response to MTX and to one or more disease-modifying anti-rheumatic drugs (DMARDs). In cases of intolerance to MTX and other DMARDs, physicians may consider the use of XELJANZ/XELJANZ XR (tofacitinib) as monotherapy. Psoriatic Arthritis XELJANZ (tofacitinib), in combination with methotrexate (MTX) or another conventional synthetic...
- Treatment of rheumatoid arthritis in patients who have not sufficiently responded to conventional treatments
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01262118 NCT01262118 · Rheumatoid Arthritis This was a single-arm, open-label, unblinded study that tracked lipid biomarker levels before and after treatment in one group of patients, with no randomized or treated comparator arm and no statistical test of a treatment effect. Registry: NCT01262118 | 1 | High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline; High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6; Cholesterol Ester Production Rate at Baseline; Cholesterol Ester Production Rate at Week 6 2012-01 | HDL cholesterol in the rheumatoid arthritis cohort on tofacitinib 10 mg twice daily: mean 54.30 mg/dL (SD 12.52) at baseline and 62.34 mg/dL (SD 15.24) at Week 6. The untreated healthy-volunteer cohort (63.43 mg/dL at baseline) is a reference group only. No statistical analysis is posted. | Weak signal | link ↗ |
View 8 more trials
NCT02566967 NCT02566967 · Rheumatoid Arthritis This was a small, single-arm, open-label dose-titration study with no randomization, no blinding, and no comparator arm, designed to find an individualized dose rather than test treatment effect against a control. Results have not been posted. Registry: NCT02566967 | 3 | Record the optimal dose of tofacitinib needed to achieve LDA or clinical remission as measured by CDAI score (one year) 2017-12 | Results not posted; external-source review pending | Weak signal | link ↗ |
NCT00814307 NCT00814307 · Rheumatoid Arthritis This was a randomized, quadruple-blind, placebo-controlled trial in 611 patients with three primary endpoints at month 3. ACR20 response (60% and 66% vs 27% on placebo) and physical function improved significantly with each dose, but remission by DAS28 (6% and 10% vs 5%) did not differ significantly, so the primary results were mixed. Registry: NCT00814307 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3; Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 (Baseline, Month 3); Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3 2010-06 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00856544 NCT00856544 · Rheumatoid Arthritis Randomized, quadruple-blind, placebo-controlled trial of 795 patients. At month 6, ACR20 response was 52.7% with tofacitinib 5 mg and 58.3% with 10 mg versus 31.2% with placebo (p<0.0001), and DAS28 remission and HAQ-DI also significantly favored tofacitinib. The limitation is that no sample-size or power calculation is reported in the registry, so the trial cannot be confirmed as adequately powered despite its strong design. Registry: NCT00856544 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6; Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 (Baseline, Month 3); Percentage of Participants Achieving Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR])Less Than 2.6 at Month 6 2011-01 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00853385 NCT00853385 · Rheumatoid Arthritis This was a randomized, quadruple-blind phase 3 trial of 717 adults with rheumatoid arthritis on methotrexate, comparing tofacitinib 5 mg and 10 mg with placebo and adalimumab. Both tofacitinib doses beat placebo on the primary ACR20 response at month 6 (about 52% vs 28%), DAS28 remission at month 6, and HAQ-DI disability score at month 3. The main limitation is that no sample-size or power calculation is reported in the record, so the trial's ability to detect its primary comparisons cannot be confirmed from the available information. Registry: NCT00853385 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6; Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Month 3 (Baseline, Month 3); Percentage of Participants With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6 2011-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00847613 NCT00847613 · Rheumatoid Arthritis A randomized, quadruple-blind, placebo-controlled trial in 800 patients. The 10 mg dose met all four primary endpoints, but the 5 mg dose missed the joint damage endpoint (p=0.0792), so the primary results are split across doses. Registry: NCT00847613 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6; Changes From Baseline in Modified Total Sharp Score (mTSS) at Month 6 (Baseline, Month 6); Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 (Baseline, Month 3); Percentage of Participant With Disease Activity Score Using 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 6 2011-04 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT00960440 NCT00960440 · Rheumatoid Arthritis A randomized, quadruple-blind, placebo-controlled trial in 399 patients in which both tofacitinib doses met all three primary endpoints against placebo. No power calculation was reported in the sources checked, so the trial cannot be confirmed as adequately sized for its primary comparisons. Registry: NCT00960440 | 3 | Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3; Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Month 3 (Baseline, Month 3); Percentage of Participants With Disease Activity Score Based on 28-Joint Count and Erythrocyte Sedimentation Rate (4 Variables) (DAS28-4 [ESR]) Less Than 2.6 at Month 3 2011-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT01039688 NCT01039688 · Rheumatoid Arthritis This was a randomized, quadruple-blind, active-controlled phase 3 trial in 956 methotrexate-naive patients with rheumatoid arthritis. Both tofacitinib doses were significantly better than methotrexate on the analyzed primary efficacy measures (change in mTSS and ACR70 at 6 months), but the registry does not report a power calculation for the primary endpoint, so the evidence is limited despite the large sample and strong design. Registry: NCT01039688 | 3 | Modified Total Sharp Score (mTSS) at Month 6; Change From Baseline at Month 6 in mTSS; Percentage of Participants Achieving American College of Rheumatology 70 (ACR70) Response at Month 6; Absolute Blood Pressure (BP) Values (mmHg) (Baseline and Months 1, 2, 3, 6, 9, 12, 15, 18, and 24); Change From Baseline in BP Values (mmHg) (Months 1, 2, 3, 6, 9, 12, 15, 18, and 24) 2013-03 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
NCT02092467 NCT02092467 · Rheumatoid Arthritis Registry: NCT02092467 | 4 | Incidence Rate of Adjudicated Malignancies Excluding Non-melanoma Skin Cancers (NMSC) (Baseline up to last contact date (maximum up to 72 months)); Incidence Rate of Adjudicated Major Adverse Cardiovascular Events (MACE) (Baseline up to last contact date (maximum up to 72 months)) 2020-07-22 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (40)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (57)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (7)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (53)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (38)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (15)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (4)
What this study did
What this study did
What this study did
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Appears in other studies (7)
Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.
Phase 2 (6)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other JAK drugs
baricitinib, upadacitinib, filgotinib, ivarmacitinib, QLM3003 and 1 more. Compare all 7 JAK drugs
Other JAK1/JAK3 drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Psoriatic Arthritis: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tofacitinib (Xeljanz): this drug | Approved | Small molecule | JAK, JAK1/JAK3 | not yet graded | No reviewed efficacy summary in this indication | |
| Abatacept (Orencia) | Approved | Protein / enzyme therapeutic | CD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cells | Reliable signal | NCT01860976: Proportion of ACR 20 Responders at Day 169 (Day 169): Abatacept 39.4% (95% CI 32.9 to 46) vs Placebo 22.3% (95% CI 16.7 to 27.9) | |
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aacf (Idacio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aaty (Yuflyma) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adaz (Hyrimoz) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Adbm (Cyltezo) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Afzb (Abrilada) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Aqvh (Yusimry) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Atto (Amjevita) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Bwwd (Hadlima) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Fkjp (Hulio) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Adalimumab-Ryvk (Simlandi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Apremilast (Otezla) | Approved | Small molecule | PDE4 | Reliable signal | NCT01212770: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 28.4% | Apremilast 30 mg 40.7% vs Placebo 18.3% NCT01172938: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16): Apremilast 20 mg 30.4% | Apremilast 30 mg 38.1% vs Placebo 19% | |
| Bimekizumab (Bimzelx) | Approved | Monoclonal antibody | IL-17A/F | Reliable signal | NCT03896581: ACR50 at week 16: bimekizumab 160 mg 43.4% (n=267) vs placebo 6.8% (n=133), odds ratio 11.14 (95% CI 5.40 to 22.97), p<0.001 (CT.gov posted results). NCT03895203: ACR50 at week 16: bimekizumab 160 mg Q4W 43.9% (n=431) vs placebo 10.0% (n=281), odds ratio 7.08 (95% CI 4.58 to 10.94), p<0.001; adalimumab reference arm 45.7% (n=140, not tested) (CT.gov posted results). | |
| Certolizumab Pegol (Cimzia) | Approved | Antibody fragment | TNF-alpha | Weak signal | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | Reliable signal | NCT04908189: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 NCT04908202: POETYK PsA-1 (NCT04908202), primary endpoint ACR20 at week 16: met, p<0.0001 | |
| Etanercept (Enbrel) | Approved | Protein / enzyme therapeutic | TNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha) | Reliable signal | NCT02376790: ACR20 response at week 24 (primary endpoint), SEAM-PsA: etanercept monotherapy 60.9% vs methotrexate monotherapy 50.7% (P=0.029); etanercept+methotrexate combination 65.0% vs methotrexate monotherapy 50.7% (P=0.005) NCT00317499: ACR20 joint response at Week 12: 59% etanercept vs 15% placebo (P < 0.0001) | |
| Golimumab (Simponi) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | NCT02181673: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 14 (Week 14): Golimumab 75.1% vs Placebo 21.8% phase 3 result · pivotal pending | |
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT04882098: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (At Week 24): Group 1: Guselkumab 100 mg q8w 68.3 percentage of participants | Group 2: Guselkumab 100 mg q4w 66.6 percentage of participants | Group 3: Placebo Followed by Guselkumab 47 percentage of participants NCT03162796: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24 (Week 24): Guselkumab 100 mg q8w 52% | Guselkumab 100 mg q4w 59.4% vs Placebo 22.2% | |
| Infliximab (Remicade) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Abda (Renflexis) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Axxq (Avsola) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Infliximab-Dyyb (Inflectra) | Approved | Monoclonal antibody | TNF-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| Ixekizumab (Taltz) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT02349295: ACR20 response at week 24 (SPIRIT-P2): placebo 23/118 (20%) vs ixekizumab Q4W 65/122 (53%), effect size 33.8% (95% CI 22.4-45.2), p<0.0001; vs ixekizumab Q2W 59/123 (48%), effect size 28.5% (95% CI 17.1-39.8), p<0.0001 NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo. | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | Reliable signal | NCT03675308: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) | |
| Secukinumab (Cosentyx) | Approved | Monoclonal antibody | IL-17 | Reliable signal | NCT04632927: HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. NCT02404350: ACR20 at week 16: secukinumab 300 mg load 62.6%, 150 mg load 55.5%, 150 mg no load 59.5% vs placebo 27.4%; odds ratios 4.58 (95% CI 3.16 to 6.63), 3.38 (2.35 to 4.87) and 4.02 (2.78 to 5.79), all p<0.0001 (CT.gov posted results). | |
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | Partial signal | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | Reliable signal | NCT03104400: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 70.6% (95% CI 66.3 to 74.9) | Upadacitinib 30 mg 78.5% (95% CI 74.6 to 82.4) vs Placebo 36.2% (95% CI 31.6 to 40.7) | Adalimumab 40 mg 65% (95% CI 60.5 to 69.5) NCT03104374: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline and Week 12): Upadacitinib 15 mg 56.9% (95% CI 50.2 to 63.6) | Upadacitinib 30 mg 63.8% (95% CI 57.4 to 70.1) vs Placebo 24.1% (95% CI 18.3 to 29.8) | |
| Ustekinumab (Stelara) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aauz (Otulfi) | Approved | — | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Aekn (Selarsdi) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Auub (Wezlana) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Hmny (Starjemza) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Srlf (Imuldosa) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Stba (Steqeyma) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Ustekinumab-Ttwe (Pyzchiva) | Approved | Monoclonal antibody | IL-12 p40 | not yet graded | No reviewed efficacy summary in this indication | |
| Icotrokinra (Icotyde) | Phase 3 | Peptide | IL-23 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Ivarmacitinib | Phase 3(overall) | Small molecule | JAK | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Netakimab | Phase 3 | Monoclonal antibody | IL-17 | Reliable signal | NCT03598751: ACR20 response at week 24: 82% (80/97) netakimab vs 9% (9/97) placebo. | |
| QLM3003 | Phase 3(overall) | Small molecule | JAK | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Sonelokimab | Phase 3 | Antibody-derived scaffold | IL-17A/F | Partial signal | NCT06641076: Primary endpoint ACR50 at week 16 met; sonelokimab 60 mg with induction: ACR50 42.1% (sponsor topline, 2026-08-10; trial blinded to week 52). NCT05640245: ACR50 response: 46% with sonelokimab 60mg and 47% with 120mg with induction, p<0.01 versus placebo; primary endpoint met (207 patients enrolled) | |
| Tirzepatide (Zepbound) | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Vunakizumab | Phase 3 | Monoclonal antibody | IL-17 | Partial signal | NCT05055934: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively | |
| Zasocitinib | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| HS-10374 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Lepzacitinib | Phase 2(overall) | Small molecule | JAK1/JAK3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| ZL-82 | Phase 2(overall) | Small molecule | JAK | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| LPX-TI641 | Phase 1 | Small molecule | TIM receptor (Treg-expanding) | not yet graded | No reviewed efficacy summary in this indication | |
| S-4321 | Phase 1 | Multispecific antibody | PD-1 / FcγRIIb (dual) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(22 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Xeljanz (tofacitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (10)
January 2027 (2)
March 2027 (2)
April 2027 (1)
What to watch
July 2027 (2)
August 2027 (1)
What to watch
October 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (3)
January 2028 (1)
What to watch
March 2028 (1)
What to watch
October 2028 (1)
What to watch
2029 (3)
April 2029 (1)
What to watch
May 2029 (1)
What to watch
December 2029 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up